IceCure Medical Ltd (NASDAQ:ICCM) Sees Large Drop in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 802,800 shares, a drop of 9.2% from the January 15th total of 883,900 shares. Currently, 3.3% of the shares of the stock are sold short. Based on an average daily volume of 607,200 shares, the short-interest ratio is currently 1.3 days.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ICCM shares. Alliance Global Partners raised shares of IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $2.50 price objective on shares of IceCure Medical in a report on Wednesday, November 27th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC increased its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,453 shares of the company’s stock after purchasing an additional 14,893 shares during the quarter. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Trading Down 0.7 %

IceCure Medical stock opened at $1.36 on Tuesday. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.45. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $1.19 and a 200-day moving average of $0.84.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings results on Tuesday, November 26th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. Equities analysts predict that IceCure Medical will post -0.28 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.